|1.||Yang, Ronghua: 16 articles (12/2015 - 01/2006)|
|2.||Schwartz, Jonathan R L: 12 articles (10/2010 - 01/2003)|
|3.||Sahakian, Barbara J: 11 articles (11/2013 - 01/2003)|
|4.||Roth, Thomas: 10 articles (12/2014 - 08/2005)|
|5.||Nishino, Seiji: 10 articles (04/2012 - 07/2006)|
|6.||Arora, Sanjay: 10 articles (12/2009 - 08/2005)|
|7.||Tufik, Sergio: 9 articles (03/2014 - 02/2008)|
|8.||Dauvilliers, Yves: 8 articles (08/2015 - 01/2003)|
|9.||Balkin, Thomas J: 8 articles (02/2012 - 01/2002)|
|10.||Frye, Mark A: 7 articles (12/2015 - 08/2007)|
06/01/1997 - "Although modafinil has proven to be a safe and effective countermeasure to the effects of extensive SD on cognitive task performance, we encourage a more comprehensive understanding of the relation between its subjective and performance enhancing effects before the drug is recommended as a viable fatigue countermeasure."
10/01/2015 - "While there was no overall significant effect on fatigue, those with greater baseline fatigue experienced improved QOL and reduced fatigue when using armodafinil. "
01/01/2014 - "Use of the wake-promoting agent modafinil results in significant improvement in subjective measures of excessive daytime sleepiness, but not of fatigue. "
02/01/2013 - "After eight weeks of therapy, there was a significant improvement in the Fatigue Assessment Scale during armodafinil treatment (median -4.5, range -20, 5) compared with placebo treatment (median 3.5, range -9, 14, P<0.05) and for the FACIT-F (armodafinil: median 9, range -12, 26 vs. placebo: median -5, range -17, 11, P<0.005). "
09/01/2012 - "After correcting for multiple comparisons of the 8 neuropsychological dependent measures, we found that the patients had significantly improved delayed memory on a list-learning task after they took armodafinil (P = 0.0005), but no improvement on measures of executive function, visual memory, processing speed, or self-reported fatigue. "
01/01/2005 - "The clinical efficacy of modafinil, combined with improved safety over CNS stimulants, has made it the most prescribed medication for the treatment of ES associated with narcolepsy. "
10/01/2011 - "Because of its high safety and low side-effect profiles, modafinil has become the first-line treatment of choice for EDS associated with narcolepsy. "
09/01/2009 - "Compared with placebo, mean sleep latency (coprimary endpoint) was significantly improved with armodafinil 150 or 250 mg once daily in patients with OSA or narcolepsy, and with armodafinil 150 mg once daily in patients with SWSD, as assessed by the Multiple Sleep Latency Test (MSLT) or the Maintenance of Wakefulness Test (MWT). "
01/15/2007 - "In conclusion, modafinil did not influence thymopsychic variables in narcolepsy, but it significantly improved cognitive performance, which may be related to medial prefrontal activity processes identified by LORETA."
04/01/2006 - "Armodafinil significantly improved ability to sustain wakefulness throughout the day in patients with narcolepsy. "
|3.||Schizophrenia (Dementia Praecox)
11/01/2010 - "In this 4-week study, adjunctive armodafinil was not associated with an improvement in cognitive measures, but armodafinil 200 mg/d appeared to mitigate the negative symptoms of schizophrenia. "
03/01/2012 - "Modafinil is a wake-promoting drug that has been shown to improve attention, memory and executive function in the healthy population and in patients with schizophrenia. "
03/01/2011 - "Modafinil is a wake-promoting drug that has been shown to improve emotion discrimination in healthy individuals and attention and executive function in schizophrenia. "
01/01/2009 - "Recently, however, modafinil has been shown to improve attentional set-shifting performance in patients with schizophrenia. "
02/01/2016 - "The objective of the present study was to assess modafinil's efficacy on subjective and objective aspects of negative symptoms of schizophrenia. "
|4.||Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
03/01/2008 - "This secondary analysis evaluated the efficacy of modafinil in children and adolescents by subtype of attention-deficit/hyperactivity disorder (ADHD) using pooled data from 3 double-blind, placebo-controlled studies. "
12/01/2006 - "In a 4-week, double-blind, placebo-controlled study, the attention-promoting agent modafinil improved symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents and was well tolerated. "
08/01/2003 - "The average Test of Variables of Attention attention-deficit hyperactivity disorder z score improved by 2.53 S.D.s for the modafinil group compared with a decline of 1.02 for control patients (P < or = 0.02). "
12/01/2006 - "Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study."
05/01/2006 - "This randomized, double-blind, placebo-controlled study assessed the efficacy and tolerability of several modafinil dosing regimens in children with attention-deficit/hyperactivity disorder (ADHD) to determine whether modafinil can be given once daily in pediatric ADHD. "
|5.||Disorders of Excessive Somnolence (Hypersomnia)
12/01/2007 - "However, the hypersomnia items on the 31-item Hamilton Depression Scale were significantly more improved with modafinil than placebo. "
12/01/2003 - "The addition of the selective psychostimulant modafinil resulted in significant improvement in the hypersomnia, with improvement in functioning. "
12/01/2003 - "The addition of modafinil to their medication regimen resulted in a decrease in hypersomnia and improvement in their level of functioning. "
03/01/2014 - "No study has up to now investigated the effect of modafinil (a reference drug to treat EDS in patients with hypersomnia) on on-road driving performance of patients suffering from central hypersomnia. "
08/01/2009 - "The aim of this study was to evaluate the efficacy and tolerability of modafinil for the treatment of hypersomnia in adults with MMD1. "
|4.||Sodium Oxybate (gamma Hydroxybutyrate)
|6.||Caffeine (No Doz)
|8.||Serotonin (5 Hydroxytryptamine)
|9.||Antidepressive Agents (Antidepressants)
|1.||Drug Therapy (Chemotherapy)
|2.||Activities of Daily Living (ADL)
|4.||Palliative Care (Palliative Medicine)
|5.||Continuous Positive Airway Pressure